Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.52 USD | +0.24% | -36.75% | -17.36% |
13/05 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
08/05 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.36% | 24Cr | |
+11.29% | 23TCr | |
+8.76% | 19TCr | |
+12.90% | 14TCr | |
+25.95% | 11TCr | |
+0.15% | 6.36TCr | |
+11.08% | 5.1TCr | |
+5.62% | 5.13TCr | |
+6.28% | 4.33TCr | |
+4.80% | 3.7TCr |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- Morgan Stanley Adjusts Price Target on NeuroPace to $4.50 From $2.50, Maintains Underweight Rating